CA3089809A1 - Compositions et procedes de traitement et de diagnostic multifonctionnels - Google Patents
Compositions et procedes de traitement et de diagnostic multifonctionnels Download PDFInfo
- Publication number
- CA3089809A1 CA3089809A1 CA3089809A CA3089809A CA3089809A1 CA 3089809 A1 CA3089809 A1 CA 3089809A1 CA 3089809 A CA3089809 A CA 3089809A CA 3089809 A CA3089809 A CA 3089809A CA 3089809 A1 CA3089809 A1 CA 3089809A1
- Authority
- CA
- Canada
- Prior art keywords
- dhn
- tmpyp
- iii
- juglone
- lll
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 157
- 239000000203 mixture Substances 0.000 title claims abstract description 143
- 238000000034 method Methods 0.000 title claims abstract description 70
- KQPYUDDGWXQXHS-UHFFFAOYSA-N juglone Chemical compound O=C1C=CC(=O)C2=C1C=CC=C2O KQPYUDDGWXQXHS-UHFFFAOYSA-N 0.000 claims abstract description 199
- VYTBDSUNRJYVHL-UHFFFAOYSA-N beta-Hydrojuglone Natural products O=C1CCC(=O)C2=C1C=CC=C2O VYTBDSUNRJYVHL-UHFFFAOYSA-N 0.000 claims abstract description 86
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 72
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 claims abstract description 56
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 42
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 39
- 238000011065 in-situ storage Methods 0.000 claims abstract description 28
- 238000003745 diagnosis Methods 0.000 claims abstract description 25
- 229910052751 metal Inorganic materials 0.000 claims abstract description 23
- 239000002184 metal Substances 0.000 claims abstract description 23
- 239000003642 reactive oxygen metabolite Substances 0.000 claims abstract description 19
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 18
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 14
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 12
- NXPPAOGUKPJVDI-UHFFFAOYSA-N naphthalene-1,2-diol Chemical compound C1=CC=CC2=C(O)C(O)=CC=C21 NXPPAOGUKPJVDI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000012458 free base Substances 0.000 claims abstract description 8
- 230000001146 hypoxic effect Effects 0.000 claims abstract description 7
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000006467 substitution reaction Methods 0.000 claims abstract description 7
- AKZFRMNXBLFDNN-UHFFFAOYSA-K meso-tetrakis(n-methyl-4-pyridyl)porphine tetrakis(p-toluenesulfonate) Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1.C1=C[N+](C)=CC=C1C(C=1C=CC(N=1)=C(C=1C=C[N+](C)=CC=1)C1=CC=C(N1)C(C=1C=C[N+](C)=CC=1)=C1C=CC(N1)=C1C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 AKZFRMNXBLFDNN-UHFFFAOYSA-K 0.000 claims description 229
- 238000007539 photo-oxidation reaction Methods 0.000 claims description 65
- 239000007864 aqueous solution Substances 0.000 claims description 61
- 230000000694 effects Effects 0.000 claims description 44
- 101100379086 Mus musculus Ankrd2 gene Proteins 0.000 claims description 40
- 230000008859 change Effects 0.000 claims description 19
- JZRYQZJSTWVBBD-UHFFFAOYSA-N pentaporphyrin i Chemical compound N1C(C=C2NC(=CC3=NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JZRYQZJSTWVBBD-UHFFFAOYSA-N 0.000 claims description 18
- 231100000252 nontoxic Toxicity 0.000 claims description 17
- 230000003000 nontoxic effect Effects 0.000 claims description 17
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 16
- 238000007254 oxidation reaction Methods 0.000 claims description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
- 239000001301 oxygen Substances 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- BOKGTLAJQHTOKE-UHFFFAOYSA-N 1,5-dihydroxynaphthalene Chemical compound C1=CC=C2C(O)=CC=CC2=C1O BOKGTLAJQHTOKE-UHFFFAOYSA-N 0.000 claims description 13
- 230000003647 oxidation Effects 0.000 claims description 13
- 239000007795 chemical reaction product Substances 0.000 claims description 12
- 150000002500 ions Chemical class 0.000 claims description 12
- 230000003247 decreasing effect Effects 0.000 claims description 11
- ABCGFHPGHXSVKI-UHFFFAOYSA-O meso-tetrakis(n-methyl-4-pyridyl)porphine(4+) Chemical compound C1=C[N+](C)=CC=C1C(C1=CC=C(N1)C(C=1C=C[N+](C)=CC=1)=C1C=CC(=N1)C(C=1C=C[N+](C)=CC=1)=C1C=CC(N1)=C1C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 ABCGFHPGHXSVKI-UHFFFAOYSA-O 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 11
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-dioxonaphthalene Natural products C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- QAJDBICYDICFCM-UHFFFAOYSA-K 5,10,15,20-tetrakis(1-methylpyridin-1-ium-4-yl)-21,22-dihydroporphyrin;tetrachloride Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].C1=C[N+](C)=CC=C1C(C1=CC=C(N1)C(C=1C=C[N+](C)=CC=1)=C1C=CC(=N1)C(C=1C=C[N+](C)=CC=1)=C1C=CC(N1)=C1C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 QAJDBICYDICFCM-UHFFFAOYSA-K 0.000 claims description 9
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 150000004820 halides Chemical group 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
- 230000007954 hypoxia Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 claims description 4
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 125000006383 alkylpyridyl group Chemical group 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000001338 necrotic effect Effects 0.000 claims description 2
- 230000001706 oxygenating effect Effects 0.000 claims description 2
- 239000007789 gas Substances 0.000 abstract description 12
- 241000894006 Bacteria Species 0.000 abstract description 11
- 150000004032 porphyrins Chemical class 0.000 abstract description 10
- 229910021645 metal ion Inorganic materials 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 150000002790 naphthalenes Chemical class 0.000 abstract description 3
- 230000008030 elimination Effects 0.000 abstract description 2
- 238000003379 elimination reaction Methods 0.000 abstract description 2
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 abstract 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 153
- -1 Fe(III) ions Chemical class 0.000 description 105
- 239000000243 solution Substances 0.000 description 87
- 238000006243 chemical reaction Methods 0.000 description 55
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 52
- 241000588724 Escherichia coli Species 0.000 description 41
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 230000009102 absorption Effects 0.000 description 20
- 238000010521 absorption reaction Methods 0.000 description 20
- 238000002428 photodynamic therapy Methods 0.000 description 19
- 229910001868 water Inorganic materials 0.000 description 17
- 238000002835 absorbance Methods 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 16
- ZUELZXZJXUXJCH-UHFFFAOYSA-N 3-[10,15,20-tris(3-hydroxyphenyl)-21,23-dihydroporphyrin-5-yl]phenol Chemical compound Oc1cccc(c1)-c1c2ccc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 ZUELZXZJXUXJCH-UHFFFAOYSA-N 0.000 description 15
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 229910052742 iron Inorganic materials 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 11
- 239000003504 photosensitizing agent Substances 0.000 description 11
- 238000006862 quantum yield reaction Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000005755 formation reaction Methods 0.000 description 8
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 229910021642 ultra pure water Inorganic materials 0.000 description 7
- 239000012498 ultrapure water Substances 0.000 description 7
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229960000907 methylthioninium chloride Drugs 0.000 description 6
- 238000005457 optimization Methods 0.000 description 6
- 208000017983 photosensitivity disease Diseases 0.000 description 6
- 231100000434 photosensitization Toxicity 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XAEPFBXVLMACNN-UHFFFAOYSA-N 3-[10,15,20-tris(3-hydroxyphenyl)-21,24-dihydroporphyrin-5-yl]phenol Chemical compound OC1=CC=CC(C=2C=3C=CC(N=3)=C(C=3C=C(O)C=CC=3)C3=CC=C(N3)C(C=3C=C(O)C=CC=3)=C3C=CC(N3)=C(C=3C=C(O)C=CC=3)C=3C=CC=2N=3)=C1 XAEPFBXVLMACNN-UHFFFAOYSA-N 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 239000010802 sludge Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000012086 standard solution Substances 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- 239000012736 aqueous medium Substances 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 230000017066 negative regulation of growth Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 229910001882 dioxygen Inorganic materials 0.000 description 3
- 238000002189 fluorescence spectrum Methods 0.000 description 3
- FLTRNWIFKITPIO-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe] FLTRNWIFKITPIO-UHFFFAOYSA-N 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- XMBSMMCPKFDGEO-ZETCQYMHSA-N (2s)-2-amino-5-[[amino-(2-methoxyethylamino)methylidene]amino]pentanoic acid Chemical compound COCCNC(=N)NCCC[C@H](N)C(O)=O XMBSMMCPKFDGEO-ZETCQYMHSA-N 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 241000283891 Kobus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005281 excited state Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001699 photocatalysis Effects 0.000 description 2
- 238000007124 photooxygenation reaction Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 102000015930 Lon proteases Human genes 0.000 description 1
- 206010024825 Loose associations Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010023294 Protease La Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- BHPNXACHQYJJJS-UHFFFAOYSA-N bacteriochlorin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)CC2)=CC=C1C=C1CCC4=N1 BHPNXACHQYJJJS-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VYLLNBWSIBGKPW-UHFFFAOYSA-O iron(3+);5,10,15,20-tetrakis(1-methylpyridin-1-ium-4-yl)-21,22-dihydroporphyrin Chemical compound [Fe+3].C1=C[N+](C)=CC=C1C(C=1C=CC(N=1)=C(C=1C=C[N+](C)=CC=1)C1=CC=C(N1)C(C=1C=C[N+](C)=CC=1)=C1C=CC(N1)=C1C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 VYLLNBWSIBGKPW-UHFFFAOYSA-O 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- MMIPFLVOWGHZQD-UHFFFAOYSA-N manganese(3+) Chemical compound [Mn+3] MMIPFLVOWGHZQD-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 108010003052 omptin outer membrane protease Proteins 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000007540 photo-reduction reaction Methods 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des compositions et des procédés multifonctionnels pour le traitement thérapeutique de bactéries et de cancers et pour le diagnostic par fluorescence. Les systèmes génèrent in situ des espèces réactives de l'oxygène telles que l'oxygène singulet (1O2), le radical hydroxyle (OH) et le juglon, et d'autres agents chimiothérapeutiques. Les procédés de l'invention produisent sélectivement de plus grandes quantités d'une espèce d'oxygène réactif par rapport aux autres. Des variantes sont efficaces dans des environnements aérobies, anaérobies ou riches H2O2 et en présence ou en l'absence de lumière. Dans un environnement riche en H2O2 en l'absence de lumière, les variantes décomposent H2O2 en gaz de O2 pour éliminer l'excès de H2O2 pour l'élimination d'environnement hypoxique. Des variantes sont formées de porphyrines, de dérivés de naphtalène et d'ions métalliques, par exemple, un noyau de porphyrine substitué par tétrakis-Ar sous forme de base libre sans substitution métallique ou d'halogénure mais ayant des substituants hydroxyphényle et alkylpyridyle à des positions méso combinés avec du dihydroxynaphtalène et des ions métalliques hydratés +3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2018/024338 WO2019190459A1 (fr) | 2018-03-26 | 2018-03-26 | Compositions et procédés de traitement et de diagnostic multifonctionnels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3089809A1 true CA3089809A1 (fr) | 2019-10-03 |
Family
ID=68059517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3089809A Pending CA3089809A1 (fr) | 2018-03-26 | 2018-03-26 | Compositions et procedes de traitement et de diagnostic multifonctionnels |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11324826B2 (fr) |
| EP (1) | EP3773561A4 (fr) |
| CA (1) | CA3089809A1 (fr) |
| SG (1) | SG11202007274UA (fr) |
| WO (1) | WO2019190459A1 (fr) |
| ZA (1) | ZA202005436B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102019102839A1 (de) * | 2019-02-05 | 2020-08-06 | Olympus Winter & Ibe Gmbh | Spülflüssigkeit für die Resektion |
| DE102019102841A1 (de) | 2019-02-05 | 2020-08-06 | Olympus Winter & Ibe Gmbh | Lösbarer Isoliereinsatz zur Verwendung in einem Resektoskop |
| WO2021086312A1 (fr) * | 2019-10-28 | 2021-05-06 | Salazar Jennie | Traitement de résistance microbienne adaptative réduite pour une maladie mangeuse de chair |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030082101A1 (en) * | 2001-06-11 | 2003-05-01 | Cavalier Discovery | Accelerators for increasing the rate of formation of free radicals and reactive oxygen species |
| AU2005271053A1 (en) * | 2004-08-09 | 2006-02-16 | Cancer Research Technology Limited | Alpha-ketoglutarates and their use as therapeutic agents |
| US9339485B2 (en) | 2007-03-02 | 2016-05-17 | University Of Maryland, Baltimore County | Plasmonic engineering of singlet oxygen and/or superoxide generation |
| US7776614B2 (en) | 2007-08-09 | 2010-08-17 | Hallstar Innovations Corp. | Test method for determining compounds capable of quenching electronic singlet state excitation of photoactive compounds |
| JP5190865B2 (ja) * | 2007-08-23 | 2013-04-24 | 国立大学法人九州大学 | ブロモ化ポルフィセン誘導体及びそれを含有する光線力学治療剤 |
| US8182785B2 (en) | 2008-06-11 | 2012-05-22 | Nutech Ventures | Methods and compositions for generating singlet oxygen |
| WO2011043502A1 (fr) | 2009-10-08 | 2011-04-14 | 국립암센터 | Composite de nanoparticules de métal-photosensibilisateur et composition pour la thérapie photodynamique ou le diagnostic comportant un tel composite |
| US8609837B2 (en) | 2010-07-06 | 2013-12-17 | Health Research, Inc. | Metallation enhancements in tumor-imaging and PDT therapy |
| US9694075B2 (en) | 2011-04-08 | 2017-07-04 | Sanovas, Inc. | Treatment of hypoxic tumors with localized oxygenation |
| JP5854407B2 (ja) | 2011-05-06 | 2016-02-09 | 国立大学法人東京工業大学 | 赤外域光による光線力学的治療又は診断剤 |
| CN103635205A (zh) | 2011-07-01 | 2014-03-12 | 思佰益药业股份有限公司 | 使用光增敏剂或5－氨基乙酰丙酸类的光动力学治疗 |
| WO2013019975A1 (fr) | 2011-08-03 | 2013-02-07 | University Of Iowa Research Foundation | Compositions et procédés de traitement du cancer |
| DE102011116165A1 (de) * | 2011-10-14 | 2013-04-18 | Merck Patent Gmbh | Benzodioxepin-3-on-Verbindungen |
| US9393306B2 (en) | 2012-04-24 | 2016-07-19 | The Board Of Regents Of The University Of Oklahoma | Singlet oxygen-labile linkers and methods of production and use thereof |
| US9145383B2 (en) | 2012-08-10 | 2015-09-29 | Hallstar Innovations Corp. | Compositions, apparatus, systems, and methods for resolving electronic excited states |
| US9867800B2 (en) | 2012-08-10 | 2018-01-16 | Hallstar Innovations Corp. | Method of quenching singlet and triplet excited states of pigments, such as porphyrin compounds, particularly protoporphyrin IX, with conjugated fused tricyclic compounds have electron withdrawing groups, to reduce generation of reactive oxygen species, particularly singlet oxygen |
| EP3210626A1 (fr) | 2016-02-26 | 2017-08-30 | biolitec Unternehmensbeteiligungs II AG | Conjugués de photosensibilisateurs porphyrinoïds avec polymères basés sur le glycérol, pour la thérapie photodynamique |
-
2018
- 2018-03-26 EP EP18913108.9A patent/EP3773561A4/fr active Pending
- 2018-03-26 CA CA3089809A patent/CA3089809A1/fr active Pending
- 2018-03-26 US US16/616,437 patent/US11324826B2/en active Active
- 2018-03-26 WO PCT/US2018/024338 patent/WO2019190459A1/fr active Search and Examination
- 2018-03-26 SG SG11202007274UA patent/SG11202007274UA/en unknown
-
2020
- 2020-08-31 ZA ZA2020/05436A patent/ZA202005436B/en unknown
- 2020-12-22 US US17/130,819 patent/US20210177970A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3773561A4 (fr) | 2021-11-24 |
| EP3773561A1 (fr) | 2021-02-17 |
| US11324826B2 (en) | 2022-05-10 |
| WO2019190459A1 (fr) | 2019-10-03 |
| SG11202007274UA (en) | 2020-08-28 |
| US20200121791A1 (en) | 2020-04-23 |
| ZA202005436B (en) | 2023-02-22 |
| US20210177970A1 (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McFarland et al. | Metal-based photosensitizers for photodynamic therapy: the future of multimodal oncology? | |
| US20210177970A1 (en) | Multifunctional Treatment And Diagnostic Compositions And Methods | |
| Wang et al. | Type I photodynamic therapy by organic–inorganic hybrid materials: From strategies to applications | |
| Callaghan et al. | The good, the bad, and the ugly–controlling singlet oxygen through design of photosensitizers and delivery systems for photodynamic therapy | |
| Zhou et al. | Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy | |
| Bonnett et al. | Porphyrins as photosensitizers | |
| Oszajca et al. | Mechanistic studies on versatile metal-assisted hydrogen peroxide activation processes for biomedical and environmental incentives | |
| Kuncewicz et al. | Perspectives of molecular and nanostructured systems with d-and f-block metals in photogeneration of reactive oxygen species for medical strategies | |
| CN103491980B (zh) | 利用红外区域光的光动力的治疗剂或诊断剂 | |
| US6410568B1 (en) | Porphyrins and their use as photosensitizer | |
| Faraggi et al. | OH radical formation by photolysis of aqueous porphyrin solutions. A spin trapping and esr study | |
| Castro et al. | The surprisingly positive effect of zinc-phthalocyanines with high photodynamic therapy efficacy of melanoma cancer | |
| Reshetnickov et al. | Novel drug form of chlorin e6 | |
| CN112409365B (zh) | 3-磺酸基丙烷巯基修饰酞菁及其制备方法与在制药领域的应用 | |
| Benniston et al. | Recent advances in photorelease complexes for therapeutic applications | |
| Cavaleiro et al. | Porphyrin derivatives: synthesis and potential applications | |
| CN113603698B (zh) | 具有i型光敏反应和光热协同效应的酞菁-奋乃静偶联物与在制药领域的应用 | |
| Köse | A novel diaxially silicon phthalocyanine sensitizer for the generation of high efficiency singlet oxygen in photochemical and sono-photochemical studies | |
| CN103254223B (zh) | 一种轴向氨基乙基苯氧基和低聚乙二醇修饰的硅酞菁 | |
| Ali | A Multifunctional Solution Composed Of TMPyP, 1, 5-DHN, And Fe (III) Ions That Produces Reactive Oxygen Species (ROS) In Aerobic, Anaerobic, And H2O2 Environments | |
| CN113717183B (zh) | 周环不对称精氨酸修饰酞菁及其制备和在制药领域的应用 | |
| US11850233B2 (en) | Reduced adaptive microbial resistance treatment for flesh eating disease (necrotizing fasciitis) | |
| Friaa et al. | Reaction of the m-THPC triplet state with the antioxidant Trolox and the anesthetic Propofol: Modulation of photosensitization mechanisms relevant to photodynamic therapy? | |
| RU2345803C2 (ru) | Способ фотоиммунотерапии фотосенсибилизатором, активируемым волновой энергией вне организма человека | |
| Sharp | Syntheses of a Tin (IV) meso-Tetra (4-pyridyl) Porphyrin Dichloride-Tetrachlorobis (Bipy) 2 Ruthenium (II) Complex and Studies of Photophysical Properties of 1-Nitropyrene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200824 |
|
| EEER | Examination request |
Effective date: 20200824 |
|
| EEER | Examination request |
Effective date: 20200824 |
|
| EEER | Examination request |
Effective date: 20200824 |
|
| EEER | Examination request |
Effective date: 20200824 |
|
| EEER | Examination request |
Effective date: 20200824 |
|
| EEER | Examination request |
Effective date: 20200824 |
|
| EEER | Examination request |
Effective date: 20200824 |